Gene therapy of the human retina (original) (raw)
Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV). In all three studies, an AAV vector was used to deliver a functional copy of the RPE65 gene, which restored vision in children suffering from LCA. These results were widely seen as a success in the gene therapy field, and have generated excitement and momentum for AAV-mediated applications in retinal disease.
| Property | Value |
|---|---|
| dbo:abstract | Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV). In all three studies, an AAV vector was used to deliver a functional copy of the RPE65 gene, which restored vision in children suffering from LCA. These results were widely seen as a success in the gene therapy field, and have generated excitement and momentum for AAV-mediated applications in retinal disease. In retinal gene therapy, the most widely used vectors for ocular gene delivery are based on adeno-associated virus. The great advantage in using adeno-associated virus for the gene therapy is that it poses minimal immune responses and mediates long-term transgene expression in a variety of retinal cell types. For example, tight junctions that form the blood-retina barrier, separate subretinal space from the blood supply, providing protection from microbes and decreasing most immune-mediated damages. There is still a lot of knowledge missing in regards of retina dystrophies. Detail characterization is needed in order to improve knowledge. To address this issue, creation of Registries is an attempt to grouped and characterize rare diseases. Registries help to localize, and measure all the phenotype of these conditions and therefore to provide easy follow-ups and provide a source of information to scientist community. Registry designs varies from region to region, however localization and characterization of the phenotype are the standard gold. Examples of Registries are: RetMxMap. A Mexican and Latin-American registry created since 2009. This registry was created by Dr Adda Lízbeth Villanueva Avilés. She is a clinical-scientist gene mapping inherited retina dystrophies in Mexico and other Latin countries. (en) La thérapie génique de la rétine est prometteuse dans le traitement de différentes formes de cécité héréditaire et non héréditaire . En thérapie génique de la rétine, les vecteurs les plus largement utilisés pour la délivrance de gènes oculaires sont basés sur le virus adéno-associé . Le grand avantage de l'utilisation du virus adéno-associé pour la thérapie génique est qu'il provoque des réponses immunitaires minimales et assure la médiation de l'expression transgénique à long terme dans une variété de types de cellules rétiniennes. Par exemple, les jonctions serrées qui forment la barrière hémato-rétinienne séparent l'espace sous-rétinien de l' approvisionnement en sang, offrant une protection contre les microbes et diminuant la plupart des dommages à médiation immunitaire. * Rétine * Thérapie génique * Rétinite pigmentaire (fr) |
| dbo:wikiPageID | 27110987 (xsd:integer) |
| dbo:wikiPageLength | 38053 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1107439924 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Rod_cells dbr:Sclera dbr:Mouse dbr:Blindness dbc:Gene_delivery dbr:Retina dbr:Cytomegalovirus dbr:Vitreous_humor dbr:Voretigene_neparvovec dbr:In_vitro dbc:Emerging_technologies dbc:Medical_genetics dbr:Cone_cells dbr:Gene_delivery dbr:Gene_therapy dbr:Gene_therapy_for_color_blindness dbr:Outer_nuclear_layer dbr:Peripheral_vision dbr:Genzyme dbr:Opsin dbr:Apoptosis dbr:Lions_Eye_Institute dbr:Choroideremia dbr:Color_blindness dbr:Photoreceptor_cell dbr:Macula_of_retina dbr:Macular_degeneration dbr:Adeno-associated_virus dbr:Tropism dbr:Codon dbr:Amino_acid dbc:Molecular_biology dbr:Doxycycline dbr:Angiogenesis dbr:Night_blindness dbr:Cell_death dbr:Protein_folding dbr:Retinal_pigment_epithelium dbr:Royal_College_of_Surgeons dbc:Gene_therapy dbr:Ischemia dbr:Tetracycline dbr:Rhodopsin dbr:VEGF dbr:Inner_limiting_membrane dbr:Microbe dbr:Rats dbr:Retinitis_pigmentosa dbr:Rod_cell dbr:Cell_tropism dbr:Immune_response dbr:Leber's_congenital_amaurosis dbr:RPE65 dbr:Transgene dbr:Retinoschisis dbr:PEDF dbr:Retinal_ganglion_cells dbr:Aqueous_humor dbr:Phototransduction dbr:Cell_surface_molecule dbr:Gene_transfer dbr:Blood_supply dbr:Glial_cell dbr:Nerve_tissue |
| dbp:wikiPageUsesTemplate | dbt:Main dbt:Reflist dbt:Use_dmy_dates |
| dcterms:subject | dbc:Gene_delivery dbc:Emerging_technologies dbc:Medical_genetics dbc:Molecular_biology dbc:Gene_therapy |
| rdf:type | yago:Abstraction100002137 yago:Act100030358 yago:Activity100407535 yago:Application100949134 yago:Event100029378 yago:Occupation100582388 yago:Profession100609953 yago:PsychologicalFeature100023100 yago:YagoPermanentlyLocatedEntity yago:Technology100949619 yago:Use100947128 yago:WikicatEmergingTechnologies |
| rdfs:comment | Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV). In all three studies, an AAV vector was used to deliver a functional copy of the RPE65 gene, which restored vision in children suffering from LCA. These results were widely seen as a success in the gene therapy field, and have generated excitement and momentum for AAV-mediated applications in retinal disease. (en) La thérapie génique de la rétine est prometteuse dans le traitement de différentes formes de cécité héréditaire et non héréditaire . En thérapie génique de la rétine, les vecteurs les plus largement utilisés pour la délivrance de gènes oculaires sont basés sur le virus adéno-associé . Le grand avantage de l'utilisation du virus adéno-associé pour la thérapie génique est qu'il provoque des réponses immunitaires minimales et assure la médiation de l'expression transgénique à long terme dans une variété de types de cellules rétiniennes. Par exemple, les jonctions serrées qui forment la barrière hémato-rétinienne séparent l'espace sous-rétinien de l' approvisionnement en sang, offrant une protection contre les microbes et diminuant la plupart des dommages à médiation immunitaire. (fr) |
| rdfs:label | Thérapie génique de la rétine humaine (fr) Gene therapy of the human retina (en) |
| owl:sameAs | freebase:Gene therapy of the human retina yago-res:Gene therapy of the human retina wikidata:Gene therapy of the human retina dbpedia-fr:Gene therapy of the human retina https://global.dbpedia.org/id/4LRf9 |
| prov:wasDerivedFrom | wikipedia-en:Gene_therapy_of_the_human_retina?oldid=1107439924&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Gene_therapy_of_the_human_retina |
| is dbo:wikiPageRedirects of | dbr:Adeno_associated_virus_and_gene_therapy_of_the_human_retina |
| is dbo:wikiPageWikiLink of | dbr:Robert_MacLaren dbr:Gene_therapy_for_color_blindness dbr:Lions_Eye_Institute dbr:Choroideremia dbr:Macular_degeneration dbr:Adeno_associated_virus_and_gene_therapy_of_the_human_retina dbr:Therapy dbr:List_of_therapies dbr:Visual_cycle dbr:Stem_cell_therapy_for_macular_degeneration |
| is rdfs:seeAlso of | dbr:Choroideremia |
| is foaf:primaryTopic of | wikipedia-en:Gene_therapy_of_the_human_retina |